Neumeier Poma Investment Counsel’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Neumeier Poma Investment Counsel’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-352,465	Closed	-$6.39M	–	42
2016 Q3	$6.39M	Sell	352,465 -138,945	-28%	-$2.71M	0.96%	35
2016 Q2	$8.09M	Sell	491,410 -419,575	-46%	-$6.79M	1.28%	34
2016 Q1	$15.1M	Buy	910,985 +171,500	+23%	+$3M	2.39%	18
2015 Q4	$16M	Buy	739,485 +478,105	+183%	+$9.31M	2.77%	16
2015 Q3	$5.18M	Buy	261,380 +4,625	+2%	+$146K	0.98%	36
2015 Q2	$8.92M	Sell	256,755 -233,295	-48%	-$7.12M	1.9%	28
2015 Q1	$12.7M	Buy	+490,050	New	+$8.98M	2.79%	16

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Neumeier Poma Investment Counsel's HZNP Position: Q4 2016 in Review

Neumeier Poma Investment Counsel sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 352,465 shares — an estimated $6.39M sold.

Neumeier Poma Investment Counsel first reported a position in HZNP in Q1 2015 and held it in 7 quarters. The position peaked at $16M in Q4 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

Neumeier Poma Investment Counsel reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
Neumeier Poma Investment Counsel sold 352,465 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $6.39M.
Neumeier Poma Investment Counsel first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 7 quarters.
Neumeier Poma Investment Counsel's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $16M in Q4 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Neumeier Poma Investment Counsel's 13F filing for Q4 2016, filed 10 Feb 2017.